Cargando…

The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells

Vandetanib, a multikinase inhibitor, is a target of drug treatments for non-small cell lung cancer (NSCLC). However, phase II and III clinical trials have not conclusively demonstrated the curative effects of vandetanib for NSCLC, and the reasons for this are unknown. In the present study, we use th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yan, Zhang, Yuanliang, Zou, Hanbing, Cai, Ning, Chen, Xiaojing, Xu, Longmei, Kong, Xianming, Liu, Peifeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342569/ https://www.ncbi.nlm.nih.gov/pubmed/25720956 http://dx.doi.org/10.1038/srep08629

Ejemplares similares

Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib
por: Andersson, Mattias K, et al.
Publicado: (2008)

Design and Synthesis of Vandetanib Derivatives Containing Nitroimidazole Groups as Tyrosine Kinase Inhibitors in Normoxia and Hypoxia
por: Wei, Huiqiang, et al.
Publicado: (2016)

Vandetanib
por: Vozniak, J. Michael, et al.
Publicado: (2012)

Radiosensitisation of Hepatocellular Carcinoma Cells by Vandetanib
por: Znati, Sami, et al.
Publicado: (2020)

Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System
por: Skubalova, Zuzana, et al.
Publicado: (2021)

Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib
por: Jáklová, Kateřina, et al.
Publicado: (2021)

Fe3O4 nanoparticles and cryoablation enhance ice crystal formation to improve the efficiency of killing breast cancer cells
por: Ye, Ping, et al.
Publicado: (2016)

PLGA-based dual targeted nanoparticles enhance miRNA transfection efficiency in hepatic carcinoma
por: Cai, Chenlei, et al.
Publicado: (2017)

Author Correction: PLGA-based dual targeted nanoparticles enhance miRNA transfection efficiency in hepatic carcinoma
por: Cai, Chenlei, et al.
Publicado: (2020)

Stevens-Johnson Syndrome Induced by Vandetanib
por: Yoon, Jimi, et al.
Publicado: (2011)

The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae
por: Wang, Kun, et al.
Publicado: (2021)

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
por: Degrauwe, Nils, et al.
Publicado: (2012)

Role of vandetanib in the management of medullary thyroid cancer
por: Brassard, Maryse, et al.
Publicado: (2012)

Selective use of vandetanib in the treatment of thyroid cancer
por: Fallahi, Poupak, et al.
Publicado: (2015)

Dermoscopic findings of perifollicular pigmentation associated with vandetanib
por: Cury-Martins, Jade, et al.
Publicado: (2018)

Investigating the effect of vandetanib and celecoxib combination on angiogenesis
por: Qadir, Abdul, et al.
Publicado: (2023)

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Vortex Keratopathy in a Patient Receiving Vandetanib for Non-Small Cell Lung Cancer
por: Ahn, Jeeyun, et al.
Publicado: (2011)

Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
por: Flanigan, Jaclyn, et al.
Publicado: (2010)

Photosensitivity Reactions to Vandetanib: Redevelopment after Sequential Treatment with Docetaxel
por: Son, Young-Min, et al.
Publicado: (2011)

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole
por: Martin, Paul, et al.
Publicado: (2012)

Long‐term cardiovascular effects of vandetanib and pazopanib in normotensive rats
por: Cooper, Samantha L., et al.
Publicado: (2019)

Vandetanib induced phototoxic reaction progressed to toxic epidermal necrolysis()
por: Gul, Busra Demirbag, et al.
Publicado: (2022)

Potent anti-tumor immunostimulatory biocompatible nanohydrogel made from DNA
por: Jiang, Jiana, et al.
Publicado: (2019)

The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells
por: Zhang, Junxia, et al.
Publicado: (2014)

Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

A secondary RET mutation in the activation loop conferring resistance to vandetanib
por: Nakaoku, Takashi, et al.
Publicado: (2018)

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
por: Fallahi, Poupak, et al.
Publicado: (2019)

Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice
por: Puhl, Ana C., et al.
Publicado: (2021)

Vandetanib-Induced Hyponatremia and Torsades De Pointes: A Case Report
por: Ashraf, Shoaib, et al.
Publicado: (2022)

Vandetanib alters the tumoricidal capacity of human breast cancer stem cells via inhibiting vasculogenic capacity
por: Haiaty, Sanya, et al.
Publicado: (2023)

Size-dependent cytotoxicity of Fe(3)O(4) nanoparticles induced by biphasic regulation of oxidative stress in different human hepatoma cells
por: Xie, Yuexia, et al.
Publicado: (2016)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Biomarkers for tyrosine kinase inhibitors in renal cell cancer
por: Coupe, Nicholas, et al.
Publicado: (2012)

Improved Glycemic Control With the Multi-Receptor Tyrosine Kinase Inhibitor Pazopanib
por: Böhm, Steffen, et al.
Publicado: (2010)

E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion
por: Glen, Hilary, et al.
Publicado: (2011)

A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib
por: Kimura-Tsuchiya, Reiko, et al.
Publicado: (2018)

Tyrosine kinase c-Abl regulates the survival of plasma cells
por: Li, Yan-Feng, et al.
Publicado: (2017)

Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
por: Grande, Enrique, et al.
Publicado: (2013)

A rare case of late-onset lichenoid photodermatitis after vandetanib therapy
por: Bota, James, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fc0c14if0fng8vd08j55rkcjoh